Make your day with CCSPA exam questions for your exam success provides legitimate and up in order to date and precise CCSPA Exam Cram with a 100% move guarantee. You require to practice queries for at least twenty-four hrs to score high inside the exam. Your own actual task in order to pass in CCSPA examination, commences with test exercise questions.

Exam Code: CCSPA Practice exam 2022 by team
Check Point Certified Security Principles Associate CCSPA
Checkpoint Principles candidate
Killexams : Checkpoint Principles candidate - BingNews Search results Killexams : Checkpoint Principles candidate - BingNews Killexams : Check Point Almost Has It All But Needs Growth
Security guard at live festivale event

BitsAndSplits/iStock via Getty Images

Mr. Gil Shwed founded and developed, what appears to be, a great company that almost has it all. Check Point Software Technologies (NASDAQ:CHKP) is highly stable, profitable, scalable, has no debt, has high returns on capital, is asset-light, and is managed by its founder. The financials from the last ten years are excellent.

A company that would have it all if it could provide decent growth. Although last quarter appeared different, latest growth rates have been below market which displays a small, but steady, loss in market share. I would argue that the management should (if possible) use the cash cushion available to invest heavily in projects with returns higher than its cost of capital, even if that will bring down its best-in-class margins, as explained by the economic profit idea. I would love to see last quarter's growth rates continue.

Data by YCharts
Data by YCharts


As stated in previous articles, CHKP is an Israeli cyber security company that benefitted from being a first mover in the computer firewall protection area. Since being founded in 1993 and later listed in 1996, the company has been successfully growing in size and consolidating its product offerings with now focusing on three major areas: network security (Quantum), cloud security (CloudGuard), and users and access security (Harmony). The revenues are then divided between products, licenses, subscriptions; and software updates and maintenance.

The cyber security business is expected to grow CAGR double digit going forward and it's benefiting from the current world instability and increased online attacks. The industry profits from the increased digitalization with also being connected to some tailwinds like cloud expansion.

It's mostly a software business with high gross margins and low capital investment requirements, but the need to innovate and overcome competition is enormous. Companies in this sector should be able to quickly adapt to new trends and technologies either by acquiring smaller businesses or organically hence the low debt and high cash on balance. This is why, in my opinion, the management is keeping a strong unleveraged balance sheet.

It's hard for me to access, besides the rearward financials check, how the products are performing in terms of quality and, more importantly, if the moat is widening or quite the opposite. The high returns call competitors from all sizes and segments into the area and changes might happen fast. Despite my concern, Check Point provides some status on hand-picked won battles with the reasoning behind them and even who they replaced.

New Contracts for Quantum

New Contracts for Quantum (CHKP Investor Presentation)

Economic Profit

The economic profit theory, explained briefly, is the idea that one should take into consideration opportunity costs when assessing the accounting results of a company. The theory is that the accounting earnings should be able to compensate (at least) the cost of capital deployed. This is a great way to estimate the value created or the "excess profits" produced. The literature also reflects a link between stock returns and the economic profit created, the more "excess returns" the better the stock performs.

It's also stated that businesses that already earn high returns on capital, like Check Point, should privilege growth above WACC over improvements to the value creation process. This idea is stated in a McKinsey article.

Historical CHKP Economic Profit

Historical CHKP Economic Profit (Seeking Alpha and Own Calculations)

Check Point Software has been great producing and also improving its value creation since 2019 by the way of less capital invested, while the operating profits have been mostly flat over the years. I believe this is the main reason for the stock underperforming its market despite delivering more returns to the shareholders than expected and required. I also noticed this to be a concern in the latest earnings report and I'm optimistic to see the results in the next few quarters.


To have a price target range supported by calculations, I've used three scenarios: a base scenario with a growth rate slightly lower than historical per-share free cash flow growth, a more optimistic scenario where they can capitalize on the latest quarter boost, and by last, a more negative approach where its FCF per share decline even with the large buybacks that they are constantly providing.

DCF Scenarios

DCF Scenarios (Own Calculations)

Final Value with MoS

Final Value with MoS (Own Calculations)

The results displayed are in line with what was expected. Because of its $3.7B cash position, they are trading at close to a 10x EV/FCF multiple which is a very interesting valuation considering the underlying business in question, even considering no growth. I believe the under $119 per share range to be an attractive entry point that adequately compensates inherent risks with a reasonable margin of safety.

Data by YCharts


Competitive Landscape - The first risk that comes to my mind when considering Check Point is the competition. Similarly to other fast-changing industries, like the pharmaceutical, software companies need to constantly Strengthen and evolve to stay ahead of the pack. This is sometimes very hard and can result in a loss of market position.

Distribution - They are surprisingly highly dependent on distribution partners. The annual report states that 40% of their 2021 sales go through just two distributors. Being this dependent on external players might be a cause for concern if they decide to negotiate prices, go bankrupt or simply leave Check Point out of their portfolio.

Security Incident - There's a possibility that a cyber security incident damages the reputation of Check Point to the point that it might affect future sales. Like the airlines, I tend to think that just one small (notorious) breach in security is enough to be fatal to the public's perception of the company.

Loss of Competitive Position - As mentioned before, failure to innovate or to keep its network effect running might result in loss of market share and reduced profitability fast.


Check Point should be a buy even believing that the growth will remain equal to historical records. The double-digit growth, developed in the last quarter update, if maintained could be the "cherry on top" upside potential to provide additional returns. It's my opinion that growth should be the priority to achieve at the moment, it should be the best way to increase value to the company even if it comes at some margin costs.

It appears to be a proven great business with stable competitive advantages that should remain that way. Management is trying to pivot the business to some high-growth areas with some latest successes. I enjoyed the "small family business vibe" from the earnings call and I think it's great that the founder maintains a 20% stake.

Sun, 02 Oct 2022 23:26:00 -0500 en text/html
Killexams : Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

Checkpoint Therapeutics, Inc

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows:

Cantor Fitzgerald’s Oncology, Hematology & HemeOnc Conference:


Wednesday, September 28, 2022


1:45 PM ET


Panel Discussion & 1x1 meetings


Trends and Challenges in Immuno-Oncology

Ladenburg Thalmann Healthcare Conference:


Thursday, September 29, 2022


10:30 AM ET


Register Here

Mr. Oliviero will be presenting at the Ladenburg Thalmann Healthcare Conference. A webcast of the presentation will be available on the News & Events page, located within the Investors section of Checkpoint’s website,, for approximately 30 days after the meeting. Checkpoint will also participate in one-on-one meetings during the conference.

About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”) intended to support one or more applications for marketing approval. Following positive topline and interim results in metastatic and locally advanced cSCC, respectively, Checkpoint intends to submit a Biologics License Application for both these indications, targeted for year-end. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit

Forward‐Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements relating to the potential differentiation of cosibelimab, including a potentially favorable safety profile as compared to the currently available anti-PD-1 therapies, the two-fold mechanism of action of cosibelimab translating into potential enhanced efficacy, projections of publication and regulatory submission timelines, and our planned price disruptive strategy generating substantial market share for cosibelimab in the U.S. Factors that could cause our actual results to differ materially include the following: our ability to successfully deliver the complete dataset from the clinical trial and complete a BLA submission on schedule as planned; the risk that topline and interim data remains subject to audit and verification procedures that may result in the final data being materially different from the topline or interim data we previously published; the risk that safety issues or trends will be observed in the clinical trial when the full safety dataset is available and analyzed; the risk that a positive primary endpoint does not translate to all, or any, secondary endpoints being met; risks that regulatory authorities will not accept an application for approval of cosibelimab based on data from the Phase 1 clinical trial; the risk that the clinical results from the Phase 1 clinical trial will not support regulatory approval of cosibelimab to treat cSCC or, if approved, that cosibelimab will not be commercially successful; risks related to our chemistry, manufacturing and controls and contract manufacturing relationships; risks related to our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks related to our need for substantial additional funds; other uncertainties inherent in research and development; our dependence on third-party suppliers; government regulation; patent and intellectual property matters; competition; and our ability to achieve the milestones we project, including the risk that the evolving and unpredictable Russia/Ukraine conflict and COVID-19 pandemic delay achievement of those milestones. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in our other filings with the U.S. Securities and Exchange Commission. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Any forward-looking statements set forth in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. This press release and prior releases are available at The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Company Contacts:
Jaclyn Jaffe and Bill Begien
Checkpoint Therapeutics, Inc.
(781) 652-4500

Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577

Media Relations Contact:
Katie Kennedy
Senior Vice President, Gregory FCA

Thu, 22 Sep 2022 01:31:00 -0500 en-US text/html
Killexams : Fighting against cancer with innovative immune checkpoint therapy

By disrupting immunological checkpoint (IC) expression, many hematological and solid tumors can evade the human body’s built-in antitumor immunity. Immune checkpoint (IC) inhibitors, a promising immunotherapy, re-regulates the activity of cytotoxic T lymphocytes and natural killer cells, re-establishing and enhancing innate immunity. 

The FDA has approved treatments that target ICs like cytotoxic T-lymphocyte antigen (CTLA-4), programmed cell death (PD-1), and its ligand (PD-L1) to treat various types of cancers.1

Despite their potential, IC therapies are often non-response in most patients, a condition termed primary resistance. Other individuals who initially respond can later experience tumor relapse and acquire resistance, referred to as acquired resistance.2

Only a small portion of patients respond to IC inhibitor medication, thus restricting its clinical use. The emphasis has therefore moved to investigating the underlying mechanisms at fault and discovering new ICs or combination treatment approaches to boost therapeutic efficacy.

Immune checkpoint inhibitor resistance mechanisms

There are two types of IC inhibitor resistance mechanisms: primary and acquired. They cover immunological identification of cancer cells, cell signaling, gene expression, DNA damage response, and T-cell activation mechanism.3

There are numerous resistance mechanisms currently identified. This article explores the main mechanisms causing both primary and acquired resistances.

Fighting against cancer with innovative immune checkpoint therapy

Figure 1. Mechanisms that may, either alone or in combination, lead to de novo or acquired resistance to immune checkpoint inhibition. Reproduced from Fares, et al.3. Image Credit: ACROBiosystems

Immune contexture

Immune contexture, also known as the tumor microenvironment, refers to immune factors extrinsic to cancer cells (immune and stromal cells, cytokines, and other biologics that influence therapeutic response). This microenvironment’s altered molecular and cellular compositions create an immunosuppressive atmosphere.

Regulatory T cells (Tregs), myeloid-derived suppressor cells, and tumor-associated macrophages all contribute to this modification through various methods, including cytokine secretion, T effector cell suppression, and elevated transforming growth factor beta.  This directly affects the primary response to IC inhibitor medication.

Fighting against cancer with innovative immune checkpoint therapy

Figure 2. Composition of solid tumors4. Image Credit: ACROBiosystems

Co-opting alternative immune checkpoints

The evolution of response, a process frequently altered in tumor malignancies, is a crucial component of the innate immune system. In contrast to the tumor microenvironment, which fosters an immunosuppressive environment, the altered immune response prevents T cell proliferation and diversification.

Multiple immunological checkpoints co-expressed together lead to a severely exhausted T-cell state that impairs effector function, causes progressive T-cell function loss, alters transcriptional states, and promotes antigen persistence.

Targeting or co-targeting these alternative checkpoint receptors could be a way to prevent acquired resistance in situations where immunological checkpoints are overactive and co-expressed.

Tumor immunogenicity

Tumor immunogenicity, also known as sensitivity to immune effector chemicals, is the last resistance mechanism to IC treatments. The number of immunogenic neoantigens perceived as foreign or tumor mutational burden (TMB) can be used to quantify tumor immunogenicity.

Immune system-interacting heterogeneous malignancies more frequently choose low TMB cancers. According to a study by Anagnostou et al. on recurrent non-small-cell lung carcinomas (NSCLC), this mechanism plays a significant role in acquired resistance.4

Novel immune checkpoint targets for immunotherapy

The importance of ICs in directing the innate immune system is evident in light of the revelations mentioned above. The development of the immune suppressive TME and altered immune response evolution can be attributed to the over- and under-expression of ICs.

Fighting against cancer with innovative immune checkpoint therapy

Figure 3. T-cell activation and co-signaling. Reproduced from Fares, et al.3. Image Credit: ACROBiosystems

The intricacy of IC inhibitor resistance and the existence of unknown mechanisms is revealed by the diversity in responsiveness to IC inhibitor therapy.

The development of new IC inhibitor therapies, therefore, holds the promise of overcoming resistance mechanisms and extending the current immunotherapies’ restricted applicability.

Fighting against cancer with innovative immune checkpoint therapy

Figure 4. LAG-3 selectively binds to stable pMHCII and inhibits the activation of CD4+ T cells that recognize stable pMHCII.6 Image Credit: ACROBiosystems

LAG-3 is a well-known IC inhibitor. LAG-3 is a significant immunosuppressive molecule that inhibits T cell cytokine synthesis, CD4/8 expansion and promotes Treg adoption to stop autoimmune disease and tissue damage.5

Blocking LAG-3 enhances other IC inhibitors while causing a positive immunological response against tumor cells. Clinical studies have shown that combining LAG-3 with PD-1 therapy enhances the therapeutic impact, but LAG-3 monotherapies only provide a mild response.

A LAG-3/PD-L1 combination therapy (Opdualag) for metastatic or unresectable melanoma received FDA approval in March 2022.8 LAG-3 inhibitors are currently being tested in more than 100 clinical trials, underscoring its promise as an IC treatment.

TIM-3 is another possible IC target. Numerous immune cells, including CD4/8 T cells, Tregs, myeloid cells, NK cells, and mast cells, express TIM3.9 The cellular variety of TIM-3 leads to the control of immune response via several cellular pathways.

Although the pathophysiology of TIM-3 in innate immunity is still unknown at this time, its function in numerous cellular pathways and the substantial preclinical data suggest TIM-3 as an immune checkpoint, making it a prospective immunotherapy therapeutic option for conditions other than cancer.

Perspectives on immune checkpoint therapies

Despite the tremendous potential of immunotherapy, primary or acquired resistance is frequently present, and the use of IC inhibitor therapies is restricted due to their specific purposes.

This is partly due to a lack of knowledge on immune checkpoint and resistance processes and a dearth of therapeutically beneficial immune checkpoint targets.

Notwithstanding the clinical and biological knowledge gaps, immunotherapies’ early encouraging outcomes and long-lasting effects cannot be disregarded. Immunotherapy has tremendous potential for revealing the mechanisms behind the human body’s innate defensive mechanisms.

ACROBiosystems is dedicated to creating and upgrading several IC proteins, inhibitor screening kits, and overexpression cell lines to hasten the creation of innovative immune therapeutics.

Fighting against cancer with innovative immune checkpoint therapy

Image Credit: ACROBiosystems


  1. Archilla-Ortega, A., Domuro, C., Marin-Liberal, J. et al. Blockade of novel immune checkpoints and new therapeuic combinaions to boost anitumor immunity. J Exp Clin Cancer Res 41, 62 (2022).
  2. Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. Jan 24;16:223-249. (2021)
  3. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Paients? Am Soc Clin Oncol Educ Book. Jan;39:147-164. (2019)
  4. Ghmkin H., Seno M. Blood and Cancer: Cancer Stem Cells as Origin of Hematopoieic Cells in Solid Tumor Microenvironments. Cells 9,1293 (2020)
  5. Anagnostou V, Smith KN, Forde PM, et al. Evoluion of neoanigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7:264-276 (2017)
  6. Maruhashi T., Okazuki T., et al. LAG-3: from molecular funcions to clinical applicaions. J. Immunother Cancer. 8(2):e001014 (2020)
  7. Marin-Acevedo, J.A., Kimbrough, E.O. & Lou, Y. Next generaion of immune checkpoint inhibitors and beyond. J Hematol Oncol 14, 45 (2021).
  8. Food and Drug Administraion. FDA approves Opdualag for unresectable or metastaic melanoma (2022).
  9. Wolf, Y., VK Kuchroo, et al. TIM3 comes of age as an inhibitory receptor. Nature Reviews Immunology 20, 173-185 (2020).

About ACROBiosystems

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control, and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.

To respond to the coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD, and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantities.

Sponsored Content Policy: publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Mon, 03 Oct 2022 03:10:00 -0500 en text/html
Killexams : BPD DUI Checkpoint No result found, try new keyword!Escape will cancel and close the window. End of dialog window. BPD DUI Checkpoint Let's talk about the treatment taking over your FYP. We've got you covered — no matter how long you've known ... Sat, 17 Sep 2022 04:42:00 -0500 text/html Killexams : Checkpoint alert: Shreveport Police Department looking for seat belt usage next week cannot provide a good user experience to your browser. To use this site and continue to benefit from our journalism and site features, please upgrade to the latest version of Chrome, Edge, Firefox or Safari.

Thu, 22 Sep 2022 13:54:00 -0500 en-US text/html
Killexams : Check Point Software Technologies Ltd

52 week range

107.54 - 149.62

  • Open113.75
  • Day High114.45
  • Day Low112.24
  • Prev Close111.85
  • 52 Week High149.62
  • 52 Week High Date03/03/22
  • 52 Week Low107.54
  • 52 Week Low Date10/13/22
  • Market Cap14.506B
  • Shares Out129.07M
  • 10 Day Average Volume0.97M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change-3.58


  • Open113.75
  • Day High114.45
  • Day Low112.24
  • Prev Close111.85
  • 52 Week High149.62
  • 52 Week High Date03/03/22
  • 52 Week Low107.54
  • 52 Week Low Date10/13/22
  • Market Cap14.506B
  • Shares Out129.07M
  • 10 Day Average Volume0.97M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change-3.58


  • EPS (TTM)6.02
  • P/E (TTM)18.68
  • Fwd P/E (NTM)14.89
  • EBITDA (TTM)924.10M
  • ROE (TTM)25.09%
  • Revenue (TTM)2.247B
  • Gross Margin (TTM)87.22%
  • Net Margin (TTM)35.15%
  • Debt To Equity (MRQ)0.00%


  • Earnings Date10/27/2022
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Thu, 13 Oct 2022 11:59:00 -0500 en text/html
Killexams : Checkpoint Surgical launches CHECKPOINT GEMINI™ Bipolar Nerve Stimulator for precise stimulation

CLEVELAND, Sept. 29, 2022 /PRNewswire/ -- Checkpoint Surgical today announced the addition of CHECKPOINT GEMINI™ to the company's industry-leading line of intraoperative nerve stimulators. An addition to the company's flagship CHECKPOINT Nerve Stimulator Portfolio, Checkpoint Gemini is designed to deliver more precise stimulation.

Checkpoint Surgical today announced the addition of CHECKPOINT GEMINI™ to the company’s industry-leading line of intraoperative nerve stimulators. An addition to the company's flagship CHECKPOINT Nerve Stimulator Portfolio, Checkpoint Gemini is designed to deliver more precise stimulation.

"This expansion of Checkpoint Surgical's stimulator portfolio ensures that we provide the surgeon with the optimal solution for clinical nerve procedures," said Derek Lewis, President, and CEO of Checkpoint Surgical. "Checkpoint Gemini complements our existing stimulators with a device optimized for precise nerve surgeries."

While CHECKPOINT GUARDIAN™ offers the clinical versatility to locate nerves through dense tissue and assess motor nerve function, the new Checkpoint Gemini allows more precise direct nerve stimulation even at the fascicular level. Gemini has been designed to provide surgeons greater clarity to determine which fascicle within a nerve is responsible for which response.

Checkpoint Gemini's precision is made possible by the device's innovative bipolar probe design, which focuses the energy delivered into a small area. This is in comparison to the monopolar probe of the Checkpoint Guardian, which delivers a broader field of stimulation. Checkpoint Gemini's focused stimulation at 32Hz provides a tetanic muscle response, even on fast-twitch muscle tissue such as that found in the face or pediatric anatomy.

Like all Checkpoint stimulators, Checkpoint Gemini's biphasic waveform delivers safe, continuous nerve activation without diminished response. Checkpoint Gemini provides the same usability features as the Checkpoint Guardian, including visual confirmation of stimulation delivery and a precise LCD status indicator of amplitude and pulse duration.

About Checkpoint Surgical

Checkpoint Surgical is a privately held medical device company based in Cleveland, Ohio. The company works with surgeons to advance the science and practice of peripheral nerve care through research, education, and innovative product development. Checkpoint Surgical's state-of-the-art nerve stimulation devices have become the standard of care for intraoperative nerve stimulation. The company is actively developing new products to support the entire continuum of intraoperative nerve care. For more information about Checkpoint Surgical, visit


Cision View original content to obtain multimedia:

SOURCE Checkpoint Surgical, Inc.

Thu, 29 Sep 2022 02:10:00 -0500 en text/html
Killexams : DWI checkpoint planned on Route 36 in Union Beach this weekend cannot provide a good user experience to your browser. To use this site and continue to benefit from our journalism and site features, please upgrade to the latest version of Chrome, Edge, Firefox or Safari.

Fri, 30 Sep 2022 08:21:00 -0500 en-US text/html
CCSPA exam dump and training guide direct download
Training Exams List